A Study to Evaluate ALN-AGT01 RVR in Adult Healthy Volunteers
Sponsored by Alnylam Pharmaceuticals
About this trial
Last updated 2 months ago
Study ID
ALN-AGT01 RVR-001
Status
Recruiting
Type
Interventional
Phase
Phase 1
Placebo
Yes
Accepting
18 to 65 Years
All
Trial Timing
Started 8 months ago
What is this trial about?
The purpose of this study is to evaluate the safety, tolerability and PK of single
ascending doses of ALN-AGT01 RVR.
What are the participation requirements?
Inclusion Criteria
- Is an adult healthy volunteer - Has a body mass index ≥18 kg/m^2 and ≤28 kg/m^2
Exclusion Criteria
- Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > upper limit of normal (ULN) - Has known human immunodeficiency virus infection; or known current or chronic hepatitis C virus or hepatitis B virus infection - Has an estimated glomerular filtration rate (eGFR) of <90 mL/min/1.73m^2 at screening Note: other protocol defined inclusion / exclusion criteria apply
For more information, view the full study details:
NCT06675565